EXAI - Exscientia - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

367.7M

Cash

329.9M

Avg Qtr Burn

-26.27M

Short % of Float

3.93%

Insider Ownership

38.50%

Institutional Own.

38.43%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EXS73565 (‘565) Details Cancer, B-cell malignancies, Chronic lymphocytic leukemia	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EXS74539 (‘539) Details Cancer	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GTAEXS617 (CDK7 inhibitor) Details Cancer, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EXS4318 (PKC-theta Inhibitor) Details Inflammatory disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EXS21546 (A2A receptor antagonist) Details Cancer, Non-small cell lung carcinoma, Renal cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.